INT46383

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 42
Total Number 53
Disease Relevance 44.03
Pain Relevance 6.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 1
blood 1
ileum 1
liver 1
abdomen 1
TRGC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
spinal inflammation 23 99.82 Very High Very High Very High
bradykinin 405 99.76 Very High Very High Very High
Inflammation 85 99.52 Very High Very High Very High
abdominal pain 163 98.76 Very High Very High Very High
Crohn's disease 10 98.68 Very High Very High Very High
Pain 157 98.52 Very High Very High Very High
depression 16 95.92 Very High Very High Very High
headache 82 95.44 Very High Very High Very High
colic 17 92.80 High High
Bioavailability 14 92.32 High High
Disease Link Frequency Relevance Heat
Hereditary Angioedema 2744 100.00 Very High Very High Very High
Urticaria 200 99.96 Very High Very High Very High
Low Back Pain 23 99.82 Very High Very High Very High
Pressure And Volume Under Development 1242 99.76 Very High Very High Very High
INFLAMMATION 106 99.52 Very High Very High Very High
Acute Abdomen 1 99.34 Very High Very High Very High
Renal Failure 3 99.28 Very High Very High Very High
Disease 452 99.18 Very High Very High Very High
Abdominal Pain 163 98.76 Very High Very High Very High
Pain 128 98.52 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because initial studies showed a functional deficiency of C1 esterase inhibitor and low C4 levels, he was treated with danazol, an attenuated androgen that has proven to be effective in the treatment of angioedema associated with C1 esterase inhibitor deficiency.
Negative_regulation (deficiency) of C1 associated with pressure and volume under development and hereditary angioedema
1) Confidence 0.55 Published 1982 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 6977562 Disease Relevance 0.97 Pain Relevance 0.06
While not being directly comparable, results of studies of C1 inhibitor in acute HAE suggest that the icatibant and C1 inhibitor are broadly similar in terms of onset of relief and time to complete resolution of symptoms.15–18,40
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
2) Confidence 0.52 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.54 Pain Relevance 0.07
While not being directly comparable, results of studies of C1 inhibitor in acute HAE suggest that the icatibant and C1 inhibitor are broadly similar in terms of onset of relief and time to complete resolution of symptoms.15–18,40
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
3) Confidence 0.52 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.47 Pain Relevance 0.07
Prophylaxis for HAE attacks is available; either with attenuated androgens which increase hepatic production of endogenous C1 inhibitor, or by antifibrinolytics such as tranexamic acid or ??
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
4) Confidence 0.52 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 1.36 Pain Relevance 0.06
Rhucin, a recombinant C1 inhibitor, given intravenously, is also currently unlicensed.52–54
Negative_regulation (inhibitor) of C1
5) Confidence 0.52 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.79 Pain Relevance 0.12
The authors demonstrated a deficiency of C1 esterase inhibitor in the blood of these patients, although the extent of the deficiency was not able to be determined.
Negative_regulation (inhibitor) of C1 in blood
6) Confidence 0.50 Published 2010 Journal BMC Blood Disord Section Body Doc Link PMC2881905 Disease Relevance 0.97 Pain Relevance 0
Nearly all other cases are type 2 HAE, which is characterized by the expression of dysfunctional C1 inhibitor.
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
7) Confidence 0.50 Published 2010 Journal BMC Blood Disord Section Body Doc Link PMC2881905 Disease Relevance 1.01 Pain Relevance 0.12
[Ascites and suspected acute abdomen in hereditary angioedema due to C1 inhibitor deficiency].
Negative_regulation (deficiency) of C1 in abdomen associated with pressure and volume under development, hereditary angioedema and acute abdomen
8) Confidence 0.44 Published 1997 Journal Dtsch. Med. Wochenschr. Section Title Doc Link 9410707 Disease Relevance 0.50 Pain Relevance 0.23
She had recurrent urticaria, C1' esterase inhibitor deficiency and radiographic studies showed Crohn's disease of the ileum.
Negative_regulation (deficiency) of C1 in ileum associated with urticaria, crohn's disease and disease
9) Confidence 0.43 Published 2000 Journal Can. J. Gastroenterol. Section Abstract Doc Link 10799088 Disease Relevance 0.89 Pain Relevance 0.31
He had angioneurotic edema with C1' esterase inhibitor deficiency.
Negative_regulation (deficiency) of C1 associated with urticaria
10) Confidence 0.43 Published 2000 Journal Can. J. Gastroenterol. Section Abstract Doc Link 10799088 Disease Relevance 0.85 Pain Relevance 0.29
Because initial studies showed a functional deficiency of C1 esterase inhibitor and low C4 levels, he was treated with danazol, an attenuated androgen that has proven to be effective in the treatment of angioedema associated with C1 esterase inhibitor deficiency.
Negative_regulation (inhibitor) of C1 associated with pressure and volume under development and hereditary angioedema
11) Confidence 0.41 Published 1982 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 6977562 Disease Relevance 0.97 Pain Relevance 0.06
C1 inhibitor is the primary endogenous inhibitor of the kallikrein-kinin (contact) cascade.
Negative_regulation (inhibitor) of C1
12) Confidence 0.39 Published 2007 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 17559913 Disease Relevance 0.71 Pain Relevance 0.13
C1 inhibitor is a serpin whose principal function is the regulation of local inflammation.
Negative_regulation (inhibitor) of C1 associated with inflammation
13) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.67 Pain Relevance 0.09
Thus, unlike C1 inhibitor, it does not contain human or other animal material.
Negative_regulation (inhibitor) of C1
14) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.90 Pain Relevance 0.45
Since icatibant does not replace C1 inhibitor, attenuate contact pathway or complement activation, or reduce bradykinin production, this may at first appear surprising.
Negative_regulation (inhibitor) of C1 associated with bradykinin
15) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.47 Pain Relevance 0.23
This has been partially addressed by the development of home therapy/self administration programs.24,55–57 Self-administration of C1 inhibitor requires a high degree of patient motivation and support, and the majority of patients who have only infrequent attacks may be less motivated to undergo the necessary training.
Negative_regulation (inhibitor) of C1
16) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.54 Pain Relevance 0.08
Recurrent attacks are likely to be a consequence of the short half-life of icatibant, although continuing overactivation of other inflammatory pathways controlled by C1 inhibitor may contribute.
Negative_regulation (inhibitor) of C1 associated with inflammation
17) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.43 Pain Relevance 0.05
Despite only recently gaining a licence in many EU countries and in the US, C1 inhibitor has been used extensively for HAE and has an impressive record.22,54,61,62 It seems likely that both C1 inhibitor and icatibant will be used, perhaps at different times in the same patient, according to circumstances.
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
18) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.33 Pain Relevance 0.07
Despite only recently gaining a licence in many EU countries and in the US, C1 inhibitor has been used extensively for HAE and has an impressive record.22,54,61,62 It seems likely that both C1 inhibitor and icatibant will be used, perhaps at different times in the same patient, according to circumstances.
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
19) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.33 Pain Relevance 0.06
Treatment of acute HAE with C1 inhibitor is most effective when given early.20 However, C1 inhibitor’s intravenous route of administration can result in delays in gaining access to treatment.
Negative_regulation (inhibitor) of C1 associated with hereditary angioedema
20) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.50 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox